News
News
Dr Sean PollockSeptember 17, 2026ABC Radio National interview - Changing Australia: Paul Keall and innovating with radiotherapy
SeeTreat co-founder Professor Paul Keall speaks with Sally Sara on innovating with radiotherapy. Prof Keall writes of this interview: "It was an honour to be invited to contribute to the ABC's Changing Australia series hosted by Sally Sara. On the question of how to bring innovations in radiotherapy to large numbers of patients I am proud that we at SeeTreat are doing just that: developing accessible technology to ensure that the radiation treatment is personalised to the patient throughout their course of therapy."
Read more
Antonia DaltonMay 19, 2026SeeTreat's ART.1-US Software is FDA Cleared for clinical use in the USA
SYDNEY, May 18, 2026 /PRNewswire/ -- SeeTreat's ART.1-US software delivering automated adaptive decision support for every patient at every treatment is cleared for use in the USA. From today, US clinics with Varian or Elekta CT linear accelerators, will be able to access daily evaluations of radiotherapy dose to patients' changing anatomy. With ART.1-US, clinical teams can now decide the right time for a new radiotherapy plan in 95+ seconds[1], and download supporting clinical documentation.
Read more
Dr Trang NguyenMay 14, 2026GenesisCare and SeeTreat to bring personalised Offline Adaptive Monitoring to more than 40 radiation oncology centres across Australia
SYDNEY, May 14, 2026 /PRNewswire/ -- Leading Australian cancer care provider, GenesisCare, is pleased to be collaborating with SeeTreat to enable suitable cancer patients access to the latest technology in offline adaptive treatment assessment. SeeTreat's ART.1 software will be rolled out at GenesisCare from July 2026 to support automated, adaptive treatment evaluation for eligible patients.
Read more
Michelle JoinerNovember 6, 2025SeeTreat's ART.1 is now CE Marked under EU MDR - Bringing Adaptive Radiotherapy to Every Clinic
SeeTreat announced today that its offline adaptive radiotherapy software, ART.1, has received CE Mark certification under the European Union Medical Device Regulation and is now available for clinical use across the European Union.
Read more
Prof. Jarad MartinOctober 19, 2025ART.1: Seamless, Safe, and Easy: A Radiation Oncologist's Perspective
Offline ART Remains the Go-To Approach As a radiation oncologist, I've seen the challenges of offline adaptive radiotherapy (ART) firsthand. Every department seems to have its own “secret sauce” for when to adapt a plan, and quite honestly, it all seems a little bit heuristic about what's being applied. That variability told me one thing: there's no universal standard, and that can make consistent, high-quality care difficult to achieve.
Read more
Adam ManoliJune 27, 2025What the Radiation Oncology Community is Saying About Adaptive Radiotherapy (ART): Insights from SeeTreat's LinkedIn Polls
Over the past few weeks, SeeTreat turned to LinkedIn to gather insights from the radiation oncology community on current practices and perspectives surrounding Adaptive Radiotherapy (ART). The results reveal both growing interest and the practical challenges of implementation.
Read more